By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...

Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Eli Lilly and Company ( NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse ...

Lone Pine Capital, established in 1997 by Stephen Mandel, is a leading hedge fund and investment advisory firm based in ...